ÂÜÀòÂÒÂ×

Kory Wentworth, CPA, is the Chief Financial Officer of Entrada Therapeutics.

Prior to joining Entrada, Mr. Wentworth was VP Finance and Treasurer, Principal Accounting Officer of bluebird bio where he led the accounting, tax, treasury, finance operations and reporting functions and was responsible for building a global finance team capable of supporting rapid operational expansion, commercial readiness for multiple product launches, equity financing and strategic collaboration arrangements.

Prior to bluebird, Mr. Wentworth held positions of increasing responsibility overseeing finance and accounting teams at Alexion Pharmaceuticals for nine years, most recently as Executive Director and Corporate Controller. Prior to his time at Alexion, Mr. Wentworth held positions at PricewaterhouseCoopers LLP of increasing responsibility for audit engagements in the Assurance and Business Advisory practice for six years.

Mr. Wentworth received his BS in Accounting from Susquehanna University and is a Certified Public Accountant in the state of Connecticut.